A couple of years ago, I published a post on 5 API Regulatory Challenges to Avoid, and it was interesting to look over the list and contemplate what updates I’d…
In a post last month, we discussed the three types of peptide production techniques Neuland uses to cGMP manufacture peptide APIs and NCEs for clients. We also mentioned some of the…
There’s an article on Piramal’s Pharma Solutions division at PharmTech about how they are encouraging pharma companies to implement green chemistry earlier in the drug development cycle. Yes, we agree…
7 ways to boost profits and reduce pharma synthesis waste At Neuland, we’re advocates of green chemistry. Not only is it better for the environment, but it’s also just logistically…
I’ve mentioned the importance of route scouting in the past. Now I’d like to share some of the properties of API synthesis that can affect the yield, purity, and delivery date…
Earlier this month, I wrote a post about the growth of interest in peptide therapeutics. I wanted to expand on that a bit and share three common Fmoc strategies we…